These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 22327495)
1. The influenza vaccine innovation system and lessons for PDPs. Huzair F Hum Vaccin Immunother; 2012 Mar; 8(3):407-10. PubMed ID: 22327495 [TBL] [Abstract][Full Text] [Related]
2. Domestic influenza vaccine production in Mexico: a state-owned and a multinational company working together for public health. Ponce-de-Leon S; Velazquez-Fernandez R; Bugarin-González J; García-Bañuelos P; Lopez-Sotelo A; Jimenez-Corona ME; Padilla-Catalan F; Cervantes-Rosales R Vaccine; 2011 Jul; 29 Suppl 1():A26-8. PubMed ID: 21684424 [TBL] [Abstract][Full Text] [Related]
3. Bringing influenza vaccines into the 21st century. Settembre EC; Dormitzer PR; Rappuoli R Hum Vaccin Immunother; 2014; 10(3):600-4. PubMed ID: 24378716 [TBL] [Abstract][Full Text] [Related]
4. Global production capacity of seasonal influenza vaccine in 2011. Partridge J; Kieny MP Vaccine; 2013 Jan; 31(5):728-31. PubMed ID: 23149268 [TBL] [Abstract][Full Text] [Related]
5. Development and strategies of cell-culture technology for influenza vaccine. Feng SZ; Jiao PR; Qi WB; Fan HY; Liao M Appl Microbiol Biotechnol; 2011 Feb; 89(4):893-902. PubMed ID: 21063703 [TBL] [Abstract][Full Text] [Related]
6. Influenza vaccines: from whole virus preparations to recombinant protein technology. Huber VC Expert Rev Vaccines; 2014 Jan; 13(1):31-42. PubMed ID: 24192014 [TBL] [Abstract][Full Text] [Related]
7. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world. Perdue ML; Bright RA Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430 [TBL] [Abstract][Full Text] [Related]
8. A key for successful development of flu vaccines: public-private collaboration--the Barcelona Vaccine Forum, Phacilitate, the Fira Palace Barcelona Spain, 21-23 June, 2010, the meeting report. Niculescu C; Balloul JM Hum Vaccin; 2010 Dec; 6(12):966-9. PubMed ID: 21487240 [No Abstract] [Full Text] [Related]
9. Development of pandemic influenza vaccine production capacity in Viet Nam. Hoa LK; Hiep LV; Be LV Vaccine; 2011 Jul; 29 Suppl 1():A34-6. PubMed ID: 21684426 [TBL] [Abstract][Full Text] [Related]
10. Influenza vaccine production for Brazil: a classic example of successful North-South bilateral technology transfer. Miyaki C; Meros M; Precioso AR; Raw I Vaccine; 2011 Jul; 29 Suppl 1():A12-5. PubMed ID: 21684420 [TBL] [Abstract][Full Text] [Related]
11. Establishment of pandemic influenza vaccine production capacity at Bio Farma, Indonesia. Suhardono M; Ugiyadi D; Nurnaeni I; Emelia I Vaccine; 2011 Jul; 29 Suppl 1():A22-5. PubMed ID: 21684423 [TBL] [Abstract][Full Text] [Related]
12. Development of influenza vaccine production capacity by the Government Pharmaceutical Organization of Thailand: addressing the threat of an influenza pandemic. Surichan S; Wirachwong P; Supachaturas W; Utid K; Theerasurakarn S; Langsanam P; Lakornrach P; Nitisaporn L; Chansikkakorn C; Vangkanonta W; Kaweepornpoj R; Poopipatpol K; Thirapakpoomanunt S; Srichainak S; Artavatkun W; Chokevivat V; Wibulpolprasert S Vaccine; 2011 Jul; 29 Suppl 1():A29-33. PubMed ID: 21684425 [TBL] [Abstract][Full Text] [Related]
13. The innovative medicines initiative: a European response to the innovation challenge. Goldman M Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619 [TBL] [Abstract][Full Text] [Related]
14. WHO influenza vaccine technology transfer initiative: role and activities of the Technical Advisory Group. Francis DP; Grohmann G Vaccine; 2011 Jul; 29 Suppl 1():A45-7. PubMed ID: 21684429 [TBL] [Abstract][Full Text] [Related]
15. Academia-pharma partnerships for novel drug discovery: essential or nice to have? Palmer M; Chaguturu R Expert Opin Drug Discov; 2017 Jun; 12(6):537-540. PubMed ID: 28394189 [No Abstract] [Full Text] [Related]
17. The development and manufacture of influenza vaccines. Buckland BC Hum Vaccin Immunother; 2015; 11(6):1357-60. PubMed ID: 25844949 [TBL] [Abstract][Full Text] [Related]
18. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791 [TBL] [Abstract][Full Text] [Related]
19. Development of health biotechnology in developing countries: can private-sector players be the prime movers? Abuduxike G; Aljunid SM Biotechnol Adv; 2012; 30(6):1589-601. PubMed ID: 22617902 [TBL] [Abstract][Full Text] [Related]
20. The development of vaccine viruses against pandemic A(H1N1) influenza. Robertson JS; Nicolson C; Harvey R; Johnson R; Major D; Guilfoyle K; Roseby S; Newman R; Collin R; Wallis C; Engelhardt OG; Wood JM; Le J; Manojkumar R; Pokorny BA; Silverman J; Devis R; Bucher D; Verity E; Agius C; Camuglia S; Ong C; Rockman S; Curtis A; Schoofs P; Zoueva O; Xie H; Li X; Lin Z; Ye Z; Chen LM; O'Neill E; Balish A; Lipatov AS; Guo Z; Isakova I; Davis CT; Rivailler P; Gustin KM; Belser JA; Maines TR; Tumpey TM; Xu X; Katz JM; Klimov A; Cox NJ; Donis RO Vaccine; 2011 Feb; 29(9):1836-43. PubMed ID: 21199698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]